

PROJECT

COMPASS

Innovating heart health for cancer care

COMPASS aims to optimise the cardiovascular health of cancer patients and survivors by developing an end-to-end, patient-centred cardio-oncology care pathway.

This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement 101253264. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe, and ECG Médica S.L. (Ascires).

62	25	€50.4M	60
PARTNERS	COUNTRIES	TOTAL BUDGET	MONTHS

Compass

IN ONE CLICK		
Coordinator	**Programme**	**Period**
King's College London & GE Healthcare	IHI JU	2026-2031
Sector	**Web**	
Health	www.compass-care.eu	

01 Challenge

Cardiotoxicity is a growing and often under-detected consequence of modern cancer therapies, with significant implications for patient survival, quality of life and healthcare systems. Current tools have limited predictive value and there is a lack of reliable biomarkers, meaning cardiovascular complications are often detected too late. At the same time, fragmentation between oncology and cardiology, together with challenges in data integration, hinders timely diagnosis, coordinated care and effective long-term patient monitoring.

02 Solution

COMPASS addresses these challenges by developing a comprehensive, patient-centred clinical pathway to improve the cardiovascular health of cancer patients and survivors. By integrating advanced diagnostics, novel biomarkers, real-world data and AI-driven analytics, the project enables earlier detection of cardiotoxicity, supports personalised treatment decisions, and facilitates continuous patient monitoring.

03 Impacts

COMPASS will deliver significant scientific, economic and societal impact by developing novel biomarkers, large-scale datasets and validated artificial intelligence models to advance research in cardio-oncology. The project will contribute to improving healthcare system efficiency by supporting the development of cost-effective, evidence-based care pathways that are integrated and harmonised across Europe. In addition, it will enhance the quality of life of cancer patients and survivors through earlier detection, more personalised care and improved long-term cardiovascular outcomes.